[go: up one dir, main page]

DK1974017T3 - Midler og fremgangsmåder til at påvirke stabiliteten af antistof producerende celler - Google Patents

Midler og fremgangsmåder til at påvirke stabiliteten af antistof producerende celler

Info

Publication number
DK1974017T3
DK1974017T3 DK06824300T DK06824300T DK1974017T3 DK 1974017 T3 DK1974017 T3 DK 1974017T3 DK 06824300 T DK06824300 T DK 06824300T DK 06824300 T DK06824300 T DK 06824300T DK 1974017 T3 DK1974017 T3 DK 1974017T3
Authority
DK
Denmark
Prior art keywords
affecting
stability
methods
producing cells
antibody producing
Prior art date
Application number
DK06824300T
Other languages
English (en)
Other versions
DK1974017T4 (da
Inventor
Hergen Spits
Ferenc Alexander Scheeren
Tim Beaumont
Sean Andrew Diehl
Original Assignee
Aimm Therapeutics Bv
Amc Amsterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37714656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1974017(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/NL2005/000848 external-priority patent/WO2007067032A1/en
Application filed by Aimm Therapeutics Bv, Amc Amsterdam filed Critical Aimm Therapeutics Bv
Publication of DK1974017T3 publication Critical patent/DK1974017T3/da
Application granted granted Critical
Publication of DK1974017T4 publication Critical patent/DK1974017T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK06824300.5T 2005-12-09 2006-12-08 Midler og fremgangsmåder til at påvirke stabiliteten af antistof producerende celler DK1974017T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/NL2005/000848 WO2007067032A1 (en) 2005-12-09 2005-12-09 Means and methods for influencing the stability of cells
EP06076211 2006-06-12
PCT/NL2006/000625 WO2007067046A1 (en) 2005-12-09 2006-12-08 Means and methods for influencing the stability of antibody producing cells

Publications (2)

Publication Number Publication Date
DK1974017T3 true DK1974017T3 (da) 2014-02-10
DK1974017T4 DK1974017T4 (da) 2023-09-25

Family

ID=37714656

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12175198.6T DK2540820T3 (da) 2005-12-09 2006-12-08 Midler og fremgangsmåder til påvirkning af stabiliteten af antistofproducerende celler
DK06824300.5T DK1974017T4 (da) 2005-12-09 2006-12-08 Midler og fremgangsmåder til at påvirke stabiliteten af antistof producerende celler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12175198.6T DK2540820T3 (da) 2005-12-09 2006-12-08 Midler og fremgangsmåder til påvirkning af stabiliteten af antistofproducerende celler

Country Status (14)

Country Link
US (3) US9127251B2 (da)
EP (3) EP1974017B2 (da)
JP (2) JP5753339B2 (da)
AU (2) AU2006323315B2 (da)
BR (2) BR122021001906B1 (da)
CA (2) CA2633157C (da)
DK (2) DK2540820T3 (da)
ES (2) ES2444465T5 (da)
FI (1) FI1974017T4 (da)
HU (1) HUE037580T2 (da)
NZ (3) NZ600075A (da)
PL (2) PL2540820T3 (da)
PT (2) PT2540820T (da)
WO (1) WO2007067046A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127251B2 (en) 2005-12-09 2015-09-08 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of antibody producing cells
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
JP5205597B2 (ja) * 2007-06-01 2013-06-05 静岡県 １細胞レベルでの抗体遺伝子の解析・同定方法
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2185718B1 (en) * 2007-08-03 2017-10-04 MUSC Foundation For Research Development Human monoclonal antibodies and methods for producing the same
EP2307453A1 (en) * 2008-06-16 2011-04-13 University Of Zurich Method of providing immunoglobulin secreting b lymphocytes and human antibodies
WO2010130636A1 (en) 2009-05-11 2010-11-18 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
EP2454283B1 (en) 2009-07-15 2018-03-14 AIMM Therapeutics B.V. Means and methods for producing high affinity antibodies
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
SI2400298T1 (sl) * 2010-05-28 2013-11-29 F. Hoffmann-La Roche Ag Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles
ES2626671T3 (es) 2010-12-02 2017-07-25 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
SG11201402780UA (en) 2011-12-02 2014-10-30 Aimm Therapeutics Bv Influenza a virus specific antibodies
US10017739B2 (en) * 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
DK2971039T3 (da) 2013-03-14 2020-04-06 Immusoft Corp Fremgangsmåder til in vitro-differentiering af hukommelses-b-celler og transduktion med vsv-g-pseudotypeomdannede virusvektorer
CN106062002B (zh) 2013-12-17 2021-05-04 埃姆医疗有限公司 抵抗骨髓增生障碍或淋巴组织增生障碍的手段和方法
DK3087177T3 (da) * 2013-12-24 2022-10-03 Kling Biotherapeutics B V Antistofproduktion ex vivo
DK3099709T3 (da) 2014-01-31 2020-02-03 Aimm Therapeutics Bv Midler og fremgangsmåder til fremstilling af stabile antistoffer
CA2953277A1 (en) * 2014-06-05 2015-12-10 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Means and methods for determining t cell recognition
US10428304B2 (en) 2014-07-02 2019-10-01 Tokyo University Of Science Foundation Method for producing B cell population
US20180002664A1 (en) * 2014-12-19 2018-01-04 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
US20180094243A1 (en) * 2015-04-03 2018-04-05 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
EP3307070B1 (en) * 2015-06-12 2025-10-29 Emory University Growth and survival compositions for cells capable of producing antibodies and methods related thereto
EP3313870B1 (en) 2015-06-24 2020-06-03 Aimm Therapeutics B.V. Aml antigens and uses thereof
SG11201805649UA (en) 2016-01-08 2018-07-30 Aimm Therapeutics Bv Therapeutic anti-cd9 antibody
AU2017367695A1 (en) 2016-12-02 2019-06-13 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
EP3576758A4 (en) 2017-01-31 2020-12-09 Vanderbilt University GENERATION OF IGE MONOCLONAL ANTIBODIES SPECIFIC TO HUMAN ALLERGENS AND HELMINTHS FOR DIAGNOSTIC AND THERAPEUTIC USE
US11125757B2 (en) 2017-05-26 2021-09-21 Emory University Methods of culturing and characterizing antibody secreting cells
WO2019113125A1 (en) * 2017-12-05 2019-06-13 Sqz Biotechnologies Company Intracellular delivery of biomolecules to modulate antibody production

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
ATE132190T1 (de) 1988-02-26 1996-01-15 Worcester Found Ex Biology Hemmung von htlv-iii durch exogene oligonukleotide
US5866757A (en) * 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
WO1994007367A1 (en) * 1992-09-29 1994-04-14 Apollon, Inc. Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
DK0664833T3 (da) 1992-10-05 1997-04-14 Hybridon Inc Terapeutisk anti-HIV oligonukletid og lægemiddel
WO1994017086A1 (en) 1993-01-25 1994-08-04 Apollon, Inc. Gene regulation by targeting putative intramolecular triple helix
US5550019A (en) * 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
WO1995006409A1 (en) 1993-09-03 1995-03-09 Systemix, Inc. Genetically modified human hematopoietic stem cells and their progeny
US6265556B1 (en) * 1994-12-02 2001-07-24 The Burnham Institute Nucleic acid encoding CD40 associated proteins
GB9425060D0 (en) * 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6001558A (en) * 1997-06-25 1999-12-14 Ortho Clinical Diagnostics, Inc. Amplification and detection of HIV-1 and/or HIV 2
CA2383563A1 (en) * 1999-09-08 2001-03-15 Genetrol Biotherapeutics, Inc High level cytokine production with enhanced cell viability
EP1083230A1 (en) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Viral replicons and viruses dependent on inducing agents
US7122180B2 (en) * 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20050009180A1 (en) * 2001-12-10 2005-01-13 Lili Yang Method for the generation of antigen-specific lymphocytes
WO2003050262A2 (en) 2001-12-10 2003-06-19 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
NZ534107A (en) 2001-12-18 2007-02-23 Cancer Rec Tech Ltd Creating and maintaining a cell line that produces a constitutively active signal transducer of activation and transcription (CA-STAT) protein
IL162111A0 (en) 2001-12-22 2005-11-20 4Antibody Ag Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo
WO2003079757A2 (en) 2002-03-20 2003-10-02 Massachusetts Institute Of Technology Hiv therapeutic
JP2004121237A (ja) * 2002-09-05 2004-04-22 Japan Science & Technology Agency 体外免疫末梢血リンパ球を用いた抗原特異的抗体
WO2004040969A1 (ja) * 2002-11-07 2004-05-21 Kumamoto Technology & Industry Foundation Ｇａｎｐ導入トランスジェニック哺乳動物及びその利用
GB2398783A (en) * 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
BRPI0408315A (pt) * 2003-03-14 2006-03-07 Wyeth Corp anticorpo isolado, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos de produzir um anticorpo, de gerar um anticorpo ou fragmento de ligação de antìgeno, de regular uma resposta imune, de tratar ou prevenir um distúrbio associado com célula imune em um paciente, de tratar ou prevenir um distúrbio hiperproliferativo em um paciente, e, kit de diagnóstico
SI1694360T1 (sl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Uporaba antagonističnih anti-CD40 protiteles za zdravljenje avtoimunskih in vnetnih bolezni in zavrnitve transplantata organa
DK1692276T3 (da) * 2003-11-19 2010-11-01 Us Gov Health & Human Serv Fremgangsmåde til induktion af udvikling og terminal differentiering af hukommelses-B-celler
GB0327384D0 (en) 2003-11-25 2003-12-31 Queen Mary & Westfield College Gene therapy
US20050238626A1 (en) * 2004-04-01 2005-10-27 Lili Yang Antigen specific T cell therapy
WO2005123923A2 (en) 2004-06-17 2005-12-29 Wolfgang Hillen Inducer specific tetracycline repressor proteins and methods of use thereof
EP1627563A1 (en) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
EP1647595A1 (en) * 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nucleic acids against viruses, in particular HIV
US7393923B2 (en) * 2004-11-08 2008-07-01 The Regents Of The University Of California Red-shifted fluorescent proteins mPlum and mRaspberry and polynucleotides encoding the same
US8337851B2 (en) 2005-05-18 2012-12-25 Novartis Ag Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject for a CD40-expressing cancer
WO2006132524A1 (en) 2005-06-06 2006-12-14 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for generating a t cell against an antigen of interest.
ES2366227T3 (es) 2005-11-17 2011-10-18 TET Systems GmbH & Co. KG Sistemas de expresión inducibles.
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
US9127251B2 (en) 2005-12-09 2015-09-08 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of antibody producing cells
BRPI0807952A2 (pt) * 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US9683226B2 (en) * 2009-04-03 2017-06-20 Medical Research Council Mutants of activation-induced cytidine deaminase (AID) and methods of use
KR101832201B1 (ko) 2009-07-15 2018-02-28 에임 쎄라퓨틱스 비.브이. 그람-양성 박테리아 특이적 결합 화합물
EP2454283B1 (en) * 2009-07-15 2018-03-14 AIMM Therapeutics B.V. Means and methods for producing high affinity antibodies
US8568726B2 (en) * 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
BR112012008173B1 (pt) 2009-10-06 2021-12-07 Medimmune Ltd Anticorpo monoclonal humano recombinante, sintético ou isolado ou uma parte funcional do mesmo que se liga especificamente à proteína f do vírus sincicial respiratório, sequência de ácido nucleico isolada ou um equivalente funcional da mesma, vetor, combinação, composição farmacêutica, usos dos mesmos e método para produzir um anticorpo ou parte funcional do mesmo
ES2626671T3 (es) 2010-12-02 2017-07-25 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
SG11201402780UA (en) 2011-12-02 2014-10-30 Aimm Therapeutics Bv Influenza a virus specific antibodies

Also Published As

Publication number Publication date
US10273454B2 (en) 2019-04-30
EP3327117A1 (en) 2018-05-30
US9822339B2 (en) 2017-11-21
EP2540820B1 (en) 2018-01-10
ES2660899T3 (es) 2018-03-26
PT1974017E (pt) 2014-02-11
ES2444465T5 (es) 2023-11-30
ES2444465T3 (es) 2014-02-25
US9127251B2 (en) 2015-09-08
PL2540820T3 (pl) 2018-05-30
AU2006323315A1 (en) 2007-06-14
NZ592159A (en) 2012-12-21
WO2007067046A1 (en) 2007-06-14
US20100113745A1 (en) 2010-05-06
CA3015416C (en) 2022-10-11
CA2633157A1 (en) 2007-06-14
JP5753547B2 (ja) 2015-07-22
EP1974017A1 (en) 2008-10-01
US20170306293A1 (en) 2017-10-26
NZ600075A (en) 2013-12-20
EP2540820A1 (en) 2013-01-02
CA2633157C (en) 2018-10-09
HUE037580T2 (hu) 2018-09-28
JP5753339B2 (ja) 2015-07-22
CA3015416A1 (en) 2007-06-14
PL1974017T3 (pl) 2014-04-30
BRPI0619579B8 (pt) 2022-01-25
FI1974017T4 (fi) 2023-09-14
US20160060598A1 (en) 2016-03-03
JP2009518033A (ja) 2009-05-07
DK2540820T3 (da) 2018-03-12
NZ569543A (en) 2012-12-21
EP1974017B1 (en) 2013-11-06
AU2006323315B2 (en) 2014-02-20
BRPI0619579A2 (pt) 2011-10-04
BRPI0619579B1 (pt) 2021-07-20
DK1974017T4 (da) 2023-09-25
EP1974017B2 (en) 2023-06-21
PL1974017T5 (pl) 2023-10-23
PT2540820T (pt) 2018-03-02
BR122021001906B1 (pt) 2022-03-29
JP2013099358A (ja) 2013-05-23
AU2014202709A1 (en) 2014-06-12
AU2014202709B2 (en) 2016-09-08

Similar Documents

Publication Publication Date Title
DK1974017T4 (da) Midler og fremgangsmåder til at påvirke stabiliteten af antistof producerende celler
DK1748077T3 (da) Fremgangsmåde til fremstilling af protein
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
LTPA2016026I1 (lt) Anti-il-17 antikūnai
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK2959774T3 (da) Fremgangsmåde til kryokonservering af sædceller
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
NO20071430L (no) Anti-OX4OL antistoffer
DK1838874T3 (da) Fremgangsmåder til regulering af stamceller
DK2030476T3 (da) Fremgangsmåde og system til forbedring af forståeligheden af lyde
DK1737891T3 (da) Anti-p-selectin-antistoffer
HRP20150176T1 (xx) Protutijela protiv miostatina
DK2102398T3 (da) Fremgangsmåde til fremstilling af en ankelsok og ankelsok opnået derved
EP1815074A4 (en) SCANNED MEMBRANE STRUCTURE
DK1852430T3 (da) Fremgangsmåde til fremstilling af proanthocyanidinoligomer
DE602005017745D1 (de) Brennstoffzellen-auseinanderbauverfahren
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
DK1952103T3 (da) Fremgangsmåde til at veje med flere vejeceller
FI20041123L (fi) Palkkirakenne
EP1766389A4 (en) METHOD OF ISOLATING CELLS
DK1870460T3 (da) Fremgangsmåder til fremstilling af proteiner med tripelhelixstruktur
DK1954713T3 (da) Modificerede grønfluorescerende proteiner og fremgangsmåder til anvendelse af samme
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK1768691T3 (da) Aequorinholdige præparater og fremgangsmåder til anvendelse af samme
IS8646A (is) Aðferð til að framleiða spendýrafrumur